Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,185
  • Shares Outstanding, K 17,289
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,130 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 159.37% ( -7.93%)
  • Historical Volatility 71.45%
  • IV Percentile 33%
  • IV Rank 23.03%
  • IV High 612.53% on 12/05/24
  • IV Low 23.75% on 10/18/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 350
  • Volume Avg (30-Day) 74
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 2,799
  • Open Int (30-Day) 2,893

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.75
  • Growth Rate Est. (year over year) +133,300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +50.27%
on 04/21/25
2.82 -1.42%
on 05/20/25
+0.85 (+44.04%)
since 04/17/25
3-Month
1.58 +75.95%
on 04/07/25
2.82 -1.42%
on 05/20/25
+0.33 (+13.47%)
since 02/20/25
52-Week
1.10 +152.73%
on 10/16/24
6.01 -53.74%
on 01/13/25
-1.28 (-31.53%)
since 05/20/24

Most Recent Stories

More News
Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among...

NRXP : 2.78 (+13.93%)
NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced...

NRXP : 2.78 (+13.93%)
NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m....

NRXP : 2.78 (+13.93%)
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute. Kadima, a leading...

NRXP : 2.78 (+13.93%)
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Q1 2025 Results on May 15

NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The company will host a conference call at 4:30 p.m....

NRXP : 2.78 (+13.93%)
BMWYY : 29.2000 (+4.58%)
NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation

NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharma company, has filed a patent application for NRX-100, its preservative-free intravenous ketamine formulation targeting suicidal depression....

NRXP : 2.78 (+13.93%)
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.

PSIL : 13.18 (+2.13%)
VXF : 185.92 (-0.20%)
NRXP : 2.78 (+13.93%)
BIB : 45.30 (+3.07%)
Best Momentum Stocks to Buy for January 6th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 6:NRx Pharmaceuticals, Inc. NRXP: This bio-pharmaceutical company has a Zacks Rank #1 and...

PDEX : 44.57 (+3.10%)
PBYI : 3.63 (+1.40%)
NRXP : 2.78 (+13.93%)
New Strong Buy Stocks for January 6th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Alaska Air Group, Inc. ALK: This airline company has seen the Zacks Consensus Estimate for its current year earnings increasing...

ALK : 52.38 (-2.26%)
PDEX : 44.57 (+3.10%)
NRXP : 2.78 (+13.93%)
AHT : 6.16 (+0.49%)
EGAN : 5.21 (+1.36%)
Best Momentum Stocks to Buy for December 30th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:CoreCard Corporation CCRD: This technology solutions and processing services company...

NRXP : 2.78 (+13.93%)
TRDA : 8.24 (+2.87%)
CCRD : 25.88 (+1.81%)

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 3.33
2nd Resistance Point 3.07
1st Resistance Point 2.93
Last Price 2.78
1st Support Level 2.53
2nd Support Level 2.27
3rd Support Level 2.13

See More

52-Week High 6.01
Fibonacci 61.8% 4.13
Fibonacci 50% 3.56
Fibonacci 38.2% 2.98
Last Price 2.78
52-Week Low 1.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar